DMT for Chronic Pain

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published: February 18, 2026
Journal: JAMA Psychiatry
Authors: Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Open Accessindividual

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways

In a within-subject pharmacoimaging study of 11 healthy psychedelic-experienced volunteers, inhaled DMT acutely reduced connectivity between the left ventral tegmental area and the right nucleus accumbens while increasing connectivity between the nucleus accumbens and anterior cingulate cortex and between the medial prefrontal cortex and anterior cingulate. These connectivity shifts correlated with changes in volition and perception and suggest a potential therapeutic mechanism for disorders of reward processing.

Published: December 12, 2025
Journal: Scientific Reports
Authors: Lima, G., Soares, C., Teixeira, M., Pais, M., Cabral, C., Rijo, P., Castelo-Branco, M.

Open Accessindividual

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

In this open-label exploratory crossover study of nine experienced ayahuasca users, three Acacia‑derived oral formulations delivering DMT plus harmala alkaloids were well tolerated, produced no clinically significant physiological changes, and elicited psychedelic effects rated comparable to (and for ACL‑010 sometimes more beneficial than) traditional ayahuasca. These findings suggest Acacia‑based DMT/harmala formulations are a feasible alternative for future clinical trials, although generalisability is limited by the small sample size and open‑label design.

Published: August 15, 2025
Journal: Frontiers in Psychiatry
Authors: Bonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J., Perkins, D., Sarris, J.

Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published: December 1, 2024
Journal: JAMA Psychiatry
Authors: Hinkle, J. T., Graziosi, M., Nayak, S., Yaden, D. B.

Open Accessindividual

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

This double-blind, placebo-controlled, cross-over study (n=10) finds that a medium dose of psilocybin (10mg/70kg) significantly reduced migraines (headaches) in the two weeks after dosing.

Published: January 1, 2021
Journal: Neurotherapeutics
Authors: Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., Pittman, B. P., Cozzi, N. V., D’Souza, D. C.

Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published: April 1, 2016
Journal: Pharmacological Reviews
Authors: Nichols, D. E.

Company

Product

Legal

DMT

Chronic Pain

Academic Research

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways

DMT and harmala alkaloids: an exploratory study of oral Acacia based formulations in healthy volunteers

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Psychedelics

Clinical Trials

Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants

Explore further